CEACAM1: a novel target of MITF in malignant melanoma

被引：0
|
作者：
Loeffek, S. [1 ,2 ]
Ullrich, N. [1 ,2 ]
Horn, S. [1 ,2 ]
Goergens, A. [3 ]
Davidson, I. [4 ]
Singer, B. B. [5 ]
Schadendorf, D. [1 ,2 ]
Goding, C. R. [6 ]
Helfrich, I. [1 ,2 ]
机构：
[1] Fac Med, Dept Dermatol, Skin Canc Unit, D-45147 Essen, Germany
[2] Univ Duisburg Essen, West German Canc Ctr, D-45147 Essen, Germany
[3] Fac Med, Inst Transfus Med, D-45147 Essen, Germany
[4] Inst Genet & Biol Mol & Cellulaire, Illkirch Graffenstaden, France
[5] Fac Med, Inst Anat, D-45147 Essen, Germany
[6] Univ Oxford, Nuffield Dept Clin Med, Ludwig Inst Canc Res, Oxford, England
来源：
EXPERIMENTAL DERMATOLOGY | 2016年 / 25卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
P216
引用
收藏
页码：E36 / E37
页数：2
相关论文
共 50 条
  • [1] CEACAM1 in Malignant Melanoma: A Diagnostic and Therapeutic Target
    Sapoznik, S.
    Ortenberg, R.
    Schachter, J.
    Markel, G.
    CURRENT TOPICS IN MEDICINAL CHEMISTRY, 2012, 12 (01) : 3 - 10
  • [2] Functional Relevance of CEACAM1 Isoforms in malignant Melanoma
    Ullrich, N.
    Breuer, C.
    Nilewski, E.
    Schadendorf, D.
    Singer, B.
    Helfrich, I
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2013, 11 (09): : 960 - 960
  • [3] MITF is a critical regulator of the carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1) in malignant melanoma
    Ullrich, Nico
    Loeffek, Stefanie
    Horn, Susanne
    Ennen, Marie
    Sanchez-del-Campo, Luis
    Zhao, Fang
    Breitenbuecher, Frank
    Davidson, Irwin
    Singer, Bernhard B.
    Schadendorf, Dirk
    Goding, Colin R.
    Helfrich, Iris
    PIGMENT CELL & MELANOMA RESEARCH, 2015, 28 (06) : 736 - 740
  • [4] Novel Immunotherapy for Malignant Melanoma with a Monoclonal Antibody That Blocks CEACAM1 Homophilic Interactions
    Ortenberg, Rona
    Sapir, Yair
    Raz, Lee
    Hershkovitz, Liat
    Ben Arav, Ayelet
    Sapoznik, Sivan
    Barshack, Iris
    Avivi, Camila
    Berkun, Yackov
    Besser, Michal J.
    Ben-Moshe, Tehila
    Schachter, Jacob
    Markel, Gal
    MOLECULAR CANCER THERAPEUTICS, 2012, 11 (06) : 1300 - 1310
  • [5] Serum CEACAM1 Correlates with Disease Progression and Survival in Malignant Melanoma Patients
    Sivan, Sapoznik
    Suzan, Faranesh
    Rona, Ortenberg
    Tamar, Hamburger
    Vivian, Barak
    Tamar, Peretz
    Jacob, Schachter
    Gal, Markel
    Michal, Lotem
    CLINICAL & DEVELOPMENTAL IMMUNOLOGY, 2012,
  • [6] CEACAM1 expression in cutaneous malignant melanoma predicts the development of metastatic disease
    Thies, A
    Moll, I
    Berger, J
    Wagener, C
    Brümmer, J
    Schulze, HJ
    Brunner, G
    Schumacher, U
    JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (10) : 2530 - 2536
  • [7] Isoform-specific function of CEACAM1 during tumorigenesis: CEACAM1-3S, a novel prognostic biomarker in malignant melanoma
    Ullrich, N.
    Heinemann, A.
    Nilewsk, E.
    Scherag, A.
    Schadendorf, D.
    Singer, B.
    Helfrich, I.
    EXPERIMENTAL DERMATOLOGY, 2014, 23 (03) : E45 - E45
  • [8] Systemic dysregulation of CEACAM1 in melanoma patients
    Gal Markel
    Rona Ortenberg
    Rachel Seidman
    Sivan Sapoznik
    Nira Koren-Morag
    Michal J. Besser
    Jair Bar
    Ronnie Shapira
    Adva Kubi
    Gil Nardini
    Ariel Tessone
    Avraham J. Treves
    Eyal Winkler
    Arie Orenstein
    Jacob Schachter
    Cancer Immunology, Immunotherapy, 2010, 59 : 215 - 230
  • [9] Systemic dysregulation of CEACAM1 in melanoma patients
    Markel, Gal
    Ortenberg, Rona
    Seidman, Rachel
    Sapoznik, Sivan
    Koren-Morag, Nira
    Besser, Michal J.
    Bar, Jair
    Shapira, Ronnie
    Kubi, Adva
    Nardini, Gil
    Tessone, Ariel
    Treves, Avraham J.
    Winkler, Eyal
    Orenstein, Arie
    Schachter, Jacob
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2010, 59 (02) : 215 - 230
  • [10] CEACAM1 as a molecular target in oral cancer
    Ma, Sai
    Wang, Zhonghua
    Li, Chao
    Liu, Zhenli
    Zhang, Xuan
    Li, Liheng
    An, Feng
    Qiao, Xiaoli
    AGING-US, 2023, 15 (16): : 8137 - 8154
12345